These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18391619)

  • 1. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN).
    Chollet P; Abrial C; Durando X; Thivat E; Tacca O; Mouret-Reynier MA; Leheurteur M; Kwiatkowski F; Dauplat J; Penault-Llorca F
    Cancer J; 2008; 14(2):128-32. PubMed ID: 18391619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
    Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
    Abrial SC; Penault-Llorca F; Delva R; Bougnoux P; Leduc B; Mouret-Reynier MA; Mery-Mignard D; Bleuse JP; Dauplat J; Curé H; Chollet P
    Breast Cancer Res Treat; 2005 Dec; 94(3):255-63. PubMed ID: 16267618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer.
    Clark BZ; Farrugia DJ; Landmann A; Diego EJ; Dabbs DJ; Puhalla SL; Jankowitz RC; Brufsky AM; Ahrendt GM; McAuliffe PF; Bhargava R
    Am J Clin Pathol; 2018 Mar; 149(4):332-343. PubMed ID: 29481634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
    Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
    Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
    Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
    Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients.
    Specht MC; Miller CL; Skolny MN; Jammallo LS; O'Toole J; Horick N; Isakoff SJ; Smith BL; Taghian AG
    Ann Surg Oncol; 2013 Sep; 20(9):2835-41. PubMed ID: 23689935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study.
    Saxena N; Hartman M; Aziz R; Rapiti E; Bhoo Pathy N; Lim SE; Iau P; Taib NA; Schaffar R; Neyroud-Caspar I; Yip CH; Lee SC; Verkooijen HM
    Eur J Cancer; 2011 May; 47(8):1186-92. PubMed ID: 21239165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.